GLMD News & Events

Galmed Pharmaceuticals announced a research collaboration agreement with Ramot at Tel Aviv University to evaluate Galmed's brain-penetrating SCD1 inhibitor, Aramchol, as a targeted therapy for metastatic brain cancer. By combining the genomic expertise of the Ben-David Lab with the advanced 3D in vitro and in vivo modeling capabilities of the Satchi-Fainaro Lab, Galmed aims to validate Aramchol's efficacy in treating p53-deficient brain metastases. The findings from the new research would also support Galmed's clinical work underway at Virginia Commonwealth University's Massey Comprehensive Cancer Center in colorectal cancers, where p53 mutations are highly prevalent. The published research by Prof. Ben-David and Prof. Satchi-Fainaro demonstrated that the loss of p53 induces profound metabolic adaptations of the tumor, facilitating metastatic colonization in the lipid-rich brain microenvironment. SCD1, an enzyme that converts saturated fatty acids into monounsaturated fatty acids, is essential for lipid synthesis and membrane production in proliferating cancer cells. Owing to SCD1 upregulation in p53-deficient tumors, its downregulation by Aramchol could potentially treat the metabolic-dependent brain tumor, as confirmed in preclinical models. The collaboration is managed by Ramot, Tel Aviv University's technology transfer company. Ramot is dedicated to bringing the groundbreaking research of Prof. Uri Ben-David and Prof. Ronit Satchi-Fainaro to the clinic. Their work on the metabolic vulnerabilities of p53-deficient tumors represents a transformative approach to treating metastatic brain cancer, offering a new path for patients with high unmet needs.

Galmed announced the breakthrough development of a brain penetrating new formulation of Aramchol. Crossing of the blood-brain barrier, or BBB, is an essential step to achieve effective treatment effects in Parkinson disease and other CNS diseases. The new Aramchol formulation is characterized by sequestration of the Aramchol in lipid nanoparticles which will be administered by subcutaneous injection for delivery across the BBB. This new Aramchol formulation was co-developed by Galmed and Barcode Nanotech, based on Barcode Nanotech's proprietary platform. Galmed's medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor position Aramchol as a therapeutic asset for synucleinopathies such as Parkinson disease, multiple systems atrophy, dementia and other CNS indications of unmet need.

Galmed announced the grant of a new Use Patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Rezdiffra for the treatment of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and liver fibrosis in South Korea. Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for MASH. The new patent extends Aramchol's patent protection worldwide to July 2042.

Galmed Pharmaceuticals issued a Letter to Shareholders from Allen Baharaff, Chief Executive Officer. "Over the past year, we have successfully expanded our therapeutic focus beyond liver disease, generating compelling new data that supports a broader clinical development path for Aramchol in oncology and cardiometabolic indications... My message to investors is clear: Galmed is well-capitalized, scientifically advancing on multiple fronts, and positioned for meaningful growth opportunities. 1. Strong Cash Position and Prudent Financial Stewardship. Galmed ended the third quarter of 2025 with approximately $19.2 million in cash and practically zero debt on our balance sheet... 2. Significant Clinical Advancements. Aramchol for MASH and liver fibrosis... Aramchol for Gastrointestinal oncology indications... Expansion Potential Beyond MASH and Oncology... Looking Ahead: In summary, I want to emphasize the following: Galmed remains financially strong, with sufficient resources to support our current strategic and clinical plans. Our scientific progress has been exceptional, with multiple breakthroughs validating and expanding the potential of Aramchol across high-value therapeutic areas. We are committed to short and long-term value creation, grounded in disciplined execution, scientific innovation, and responsible financial stewardship. Throughout this process, we aim to maintain transparency, careful capital allocation, and clear communication with our shareholders."